(redirected from bronchodilation)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to bronchodilator

a drug that relaxes and dilates the bronchial passageways and improves the passages of air into the lungs

References in periodicals archive ?
In a study of monodisperse albuterol aerosols (1.5, 3.0, and 6.0 [micro]m) in patients with asthma, improved bronchodilation was achieved with larger particles that resulted in lower lung doses compared with an equivalent dose of smaller particles [87].
Busse et al., "Lung function in adults with stable but severe asthma: Air trapping and incomplete reversal of obstruction with bronchodilation," Journal of Applied Physiology, vol.
Current drug therapy for stable COPD focuses primarily on bronchodilation through inhaled beta2-agonists and anticholinergic agents, immunisation, and elimination of smoking as a risk factor.
For acute episodes of short-acting bronchodilators, systemic corticosteroids, and ipratropium are used to induce rapid bronchodilation and reduce spasm.
Long-acting bronchodilation witlI once-daily dosing of tiotropium (Spiriva) in stable chrenic obstructive pulmonary disease.
A significant increase in these values has occurred following bronchodilation. Good bronchodilator reversibility bronchodilator response (BDR) is indicated by postbronchodilator increase in FEV1 by 200 mL or >12%.
Long-acting agents, such as salmeterol, formoterol, and arformoterol are indicated for maintenance bronchodilation and control of bronchospasm, and for control of nocturnal symptoms in asthma or other obstructive diseases.
[13] Meraz E, Nazeran H, Goldman M, Diong B: Respiratory System Model Parameters Track Changes in Lung Function after Bronchodilation. In proceedings of the 25th Southern Biomedical Engineering Conference, Miami, Florida.
The dual bronchodilation provided by indacaterol/glycopyrronium is delivered through our patented Breezhaler device, a single-dose dry powder inhaler with low-airflow resistance, making it suitable for patients with different severity of airflow limitation.
For the primary outcome parameters (relative change of [FEV.sub.1] and [MEF.sub.75-25] before bronchodilation) no treatment effect could be detected in the cross-over analysis ([FEV.sub.1], p = 0.6763 and [MEF.sub.75-25] p = 0.6953).
Non-selective beta-blockers may exacerbate respiratory conditions such as asthma, emphysema and chronic obstructive pulmonary disease (COPD) due to systemic absorption and subsequent respiratory ([[beta].sub.2]) receptor blockage (preventing resultant bronchodilation).
It has been suggested that inhaled salbutamol may result in a performance improvement by causing a significant bronchodilation in the airways of non-asthmatics leading to an improved [V.sub.E] and increased oxygen uptake during exercise.
Overlap can be diagnosed by one major criterion and two of the following: response to bronchodilation at least two separate times (>12% and >200 mL in FE[V.sub.1]), history of atopy, and increased total serum IgE.